Skip to main content
T

Technical Ventures RX Corp. — Investor Relations & Filings

TSXV Professional, scientific and technical activities
Filings indexed 0 across all filing types
Latest filing no filings yet
Country CA Canada
Listing TSXV

About Technical Ventures RX Corp.

Technical Ventures RX Corp. was the corporate vehicle for a Qualifying Transaction completed in 2014, resulting in the acquisition of TheraVitae Inc. (TVI). The resulting clinical-stage biotechnology operation focuses on the development and commercialization of innovative, autologous (patient's own), blood-derived cell therapies. The company utilizes a proprietary technology platform engineered for the treatment of vascular diseases. Its lead clinical-stage candidate is ACP-01, an autologous cell therapy currently being advanced through clinical trials for vascular applications. This specialization in regenerative medicine leverages the patient's own biological material for personalized therapeutic interventions.

Recent filings

No filings indexed yet

We are still gathering filings for Technical Ventures RX Corp.. .

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.